EichorEICHOR
Location: Mount Vernon Synced from ClinicalTrials.gov · August 07, 2026

Clinical studies recruiting near Mount Vernon

Studies with at least one listed site matching this location on the public registry. Each page explains the study in plain language, with locations and study-team contacts. Clinicians: generate a printable list for your patient →

This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in
Phase 3 · Pfizer · NCT06758401In Vivo Dosimetry for Brachytherapy Study
Phase N/A · East and North Hertfordshire NHS Trust · NCT06863090Adjuvant Tebentafusp in High Risk Ocular Melanoma
Phase 3 · European Organisation for Research and Treatment of Cancer - · NCT06246149A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KR
Phase 3 · Eli Lilly and Company · NCT06119581Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)
Phase 3 · Immunocore Ltd · NCT05549297A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With
Phase 3 · Hoffmann-La Roche · NCT05894239ARISTOCRAT: Blinded Trial of Temozolomide +/- Cannabinoids
Phase 2 · University of Birmingham · NCT05629702A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurre
Phase 3 · Janssen Research & Development, LLC · NCT07276399International Registry for Men With Advanced Prostate Cancer (IRONMAN)
Phase N/A · Prostate Cancer Clinical Trials Consortium · NCT03151629A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Le
Phase 3 · Hoffmann-La Roche · NCT06790693Efficacy and Safety Study of Rimegepant for the Preventative Treatment of Migraine in Pediatric Subjects
Phase 3 · Pfizer · NCT05156398Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-posi
Phase 3 · Jazz Pharmaceuticals · NCT06282575A Trial of Early Detection of Molecular Relapse With Circulating Tumour DNA Tracking and Treatment With Palbociclib Plus
Phase 2 · Royal Marsden NHS Foundation Trust · NCT04985266A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Parti
Phase 3 · Merck Sharp & Dohme LLC · NCT06312137A Clinical Trial Investigating the Safety, Tolerability, and Therapeutic Effects of BNT113 in Combination With Pembroliz
Phase 2/Phase 3 · BioNTech SE · NCT04534205Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participa
Phase 3 · Amgen · NCT06252649A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin)
Phase 1/Phase 2 · Eisai Inc. · NCT04300556Safety and Efficacy of VB10.16 and Pembrolizumab in Patients with Head-Neck Squamous Cell Carcinoma
Phase 1/Phase 2 · Nykode Therapeutics ASA · NCT06016920A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resist
Phase 3 · Merck Sharp & Dohme LLC · NCT06136650Renal Adjuvant MultiPle Arm Randomised Trial
Phase 3 · University College, London · NCT03288532MILD® Percutaneous Image-Guided Lumbar Decompression: A Medicare Claims Study
Phase N/A · Montefiore Mount Vernon · Stryker Instruments · NCT03072927Personalized Medicine for Advanced Biliary Cancer Patients
Phase 3 · UNICANCER · NCT05615818A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Parti
Phase 3 · Janssen Research & Development, LLC · NCT06662786A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants Wit
Phase 3 · Celgene · NCT06764485To Study the Effect of Inavolisib in Combination With Fulvestrant in Participants With Breast Cancer
Phase 2 · Hoffmann-La Roche · NCT07368998A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)
Phase 3 · Merck Sharp & Dohme LLC · NCT06925737Modi-1 Moditope in Breast, Head and Neck, Ovarian, or Renal Cancer
Phase 1/Phase 2 · Scancell Ltd · NCT05329532A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild
Phase 3 · Janssen Research & Development, LLC · NCT06750094EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblast
Phase 3 · NovoCure GmbH · NCT06556563A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresec
Phase 3 · Bristol-Myers Squibb · NCT07361497
Look up another city
Look up another condition
Eichor
Clinical intelligence from public evidence
Use of Eichor is governed by our Terms of Use · Privacy Policy
© 2026 Biomedistats LLC (dba Eichor)

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.